Clinical-stage specialty pharmaceutical firm Carbylan Therapeutics has completed the enrolment of patients in its 510 subject COR1.1 Phase III pivotal trial of Hydros-TA for the treatment of pain associated with osteoarthritis.
Hydros-TA is a proprietary and cross-linked combination of low dose corticosteroid and novel hyaluronic acid viscosupplement, which is being developed to provide both rapid and sustained osteoarthritis pain relief through a single intra-articular injection.
Go deeper with GlobalData
The company has enrolled subjects at 30 clinical sites in Canada, Australia, New Zealand, Netherlands, Hungary and Curacao.
COR1.1 is the first of two pivotal trials of Hydros-TA, which were designed by the firm as part of its Phase III programme.
Carbylan Therapeutics president and CEO David Renzi said: "The completion of COR1.1 subject enrolment is a significant milestone for Carbylan and an important step toward our goal of bringing Hydros-TA to market."
The study included subjects with Kellgren-Lawrence Grade 2 and 3 osteoarthritis (OA) of the knee and they were randomized equally between three treatment arms Hydros-TA, Hydros and Triamcinolone Acetonide (TA).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to the firm, the objective of the study is to show the safety and efficacy of Hydros-TA and the contribution of each of the two components in this therapy.
The primary endpoints of the trial will be change from baseline in WOMAC A (pain) subscale scores for Hydros-TA versus Hydros at two weeks and Hydros-TA versus TA at 26 weeks.
Secondary endpoints will be WOMAC C (function) changes, subject and physician global assessment changes and OMERACT_OARSI responder analysis.
Carbylan plans to reveal the top-line data from this trial in early 2016.
Image: Severe osteoarthritis and osteopenia of the carpal joint and 1st carpometacarpel joint. Photo: courtesy of James Heilman, MD.
